Although the COVID-19 pandemic has had a short-term negative impact on the US advanced visualization system market, the market will grow slowly over the forecast period, supported by increasing demand for cardiology and oncology imaging procedures among the country’s aging population. However, the pace of market growth will be limited by the saturated nature of the US advanced visualization system market and the ongoing shift toward thin-client solutions among the country’s increasingly consolidated healthcare facilities.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for advanced visualization systems in the US across an 11-year period.
The COVID-19 pandemic has affected the advanced visualization system market.
To what extent has the COVID-19 pandemic impacted the advanced visualization system market?
How has the impact of the pandemic varied across specialties?
How quickly are procedure volumes expected to rebound?
The US advanced visualization system market has been transitioning away from thick-client workstations and toward thin- or zero-client solutions.
What impact is this having on unit sales and ASPs in this market?
How will competitors attract clients as the industry shifts to thin- or zero-client solutions?
Interest in the incorporation of AI technologies in advanced visualization systems continues to rise.
Which companies are integrating such technologies into their offerings?
To what extent will these technologies improve adoption of advanced visualization systems in the United States?
While the overall US market will grow slowly, there are particular opportunities for growth in the radiology, cardiology, and oncology spaces.
What factors are driving the adoption of advanced visualization applications in radiology, cardiology, and oncology departments?
Is the growth in imaging-intensive procedures in these departments sustainable over the forecast period?
Which companies are the leaders in this space? What strategies are they using to remain competitive?
Which procedures will drive the adoption of advanced visualization applications over the forecast period?
What diagnostic and non-diagnostic needs are companies looking to cater to?
Many PACS vendors are pulling advanced visualization capability into enterprise-wide PACS solutions.
How are competitors in this space, particularly independent application vendors and imaging modality vendors, reacting to this development?
What advantages does a facility have if it decides to integrate its advanced visualization software directly into its PACS?